Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4452660
Max Phase: Preclinical
Molecular Formula: C49H75N13O21
Molecular Weight: 1182.21
Molecule Type: Unknown
Associated Items:
ID: ALA4452660
Max Phase: Preclinical
Molecular Formula: C49H75N13O21
Molecular Weight: 1182.21
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)O
Standard InChI: InChI=1S/C49H75N13O21/c1-21(2)12-27(43(76)58-29(14-24-6-8-25(65)9-7-24)45(78)57-26(10-11-34(50)66)42(75)61-32(49(82)83)15-35(51)67)55-36(68)18-53-41(74)30(16-38(70)71)59-47(80)33(20-63)62-46(79)31(17-39(72)73)60-44(77)28(13-22(3)4)56-37(69)19-54-48(81)40(52)23(5)64/h6-9,21-23,26-33,40,63-65H,10-20,52H2,1-5H3,(H2,50,66)(H2,51,67)(H,53,74)(H,54,81)(H,55,68)(H,56,69)(H,57,78)(H,58,76)(H,59,80)(H,60,77)(H,61,75)(H,62,79)(H,70,71)(H,72,73)(H,82,83)/t23-,26+,27+,28+,29+,30+,31+,32+,33+,40+/m1/s1
Standard InChI Key: JQQLHEJTTIUEQZ-BIHPYDIESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1182.21 | Molecular Weight (Monoisotopic): 1181.5200 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Miao Q, Ma K, Chen D, Wu X, Jiang S.. (2019) Targeting tropomyosin receptor kinase for cancer therapy., 175 [PMID:31077998] [10.1016/j.ejmech.2019.04.053] |
Source(1):